

Resource Summary Report

Generated by [RRID](#) on Sep 4, 2026

OE33

RRID:CVCL_0471

Type: Cell Line

Proper Citation

RRID:CVCL_0471

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0471

Proper Citation: RRID:CVCL_0471

Description: Cell line OE33 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Barrett adenocarcinoma

Defining Citation: [PMID:9010035](#), [PMID:11520067](#), [PMID:20075370](#), [PMID:20215515](#), [PMID:22460905](#), [PMID:23795680](#), [PMID:25877200](#), [PMID:25984343](#), [PMID:26512696](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:27594985](#), [PMID:27600491](#), [PMID:28196595](#), [PMID:28504813](#), [PMID:30894373](#), [PMID:30971826](#), [PMID:31068700](#), [PMID:31395879](#), [PMID:31978347](#), [PMID:35839778](#)

Comments: Population: Caucasian., Part of: TCGA-110-CL cell line panel., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: OE33

Synonyms: OE-33, JROECL 33, JROECL33, OEC33

Cross References: BTO:BTO_0003541, CLO:CLO_0008240, EFO:EFO_0002310, MCCL:MCC:0000369, CLDB:cl3762, AddexBio:C0013003/115, AddexBio:C0013004/121, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, BioGRID_ORCS_Cell_line:395, BioSample:SAMN03472890, BioSample:SAMN03473392, BioSample:SAMN10987775,

cancer cell lines: CVCL_0471, Cell_Model_Passport: SIDM00477, ChEMBL-Cells: ChEMBL3308776, ChEMBL-Targets: ChEMBL1075556, Cosmic: 871233, Cosmic: 910549, Cosmic: 978855, Cosmic: 997861, Cosmic: 1175877, Cosmic: 1599343, Cosmic: 1618820, Cosmic-CLP: 910549, DepMap: ACH-000383, DSMZ: ACC-706, DSMZCellDive: ACC-706, ECACC: 96070808, EGA: EGAS00001000978, GDSC: 910549, GEO: GSE36840, GEO: GSM827306, GEO: GSM887476, GEO: GSM888557, GEO: GSM1375731, GEO: GSM1375732, GEO: GSM1375733, GEO: GSM1375734, GEO: GSM1375743, GEO: GSM1375744, GEO: GSM1375745, GEO: GSM1375746, GEO: GSM1375755, GEO: GSM1375756, GEO: GSM1375757, GEO: GSM1375758, GEO: GSM1670304, GEO: GSM3258552, IARC_TP53: 21601, IGRhCellID: OE33, LiGeA: CCLE_490, LINCS_LDP: LCL-1797, PharmacDB: OE33_1196_2019, PRIDE: PXD030304, Progenetix: CVCL_0471, PubChem_Cell_line: CVCL_0471, Wikidata: Q54931865

ID: CVCL_0471

Record Creation Time: 20220427T221356+0000

Record Last Update: 20260904T015330+0000

Ratings and Alerts

No rating or validation information has been found for OE33.

No alerts have been found for OE33.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 14 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#).

Zheng X, et al. (2026) Integrative bioinformatics and experiments identify RIBC2 as a key regulator in the esophageal cancer. PloS one, 21(2), e0340850.

Ai ZE, et al. (2026) Targeting ADAR1 p150 triggers tumor inhibition and antitumor immunity to overcome immunotherapy resistance. iScience, 29(6), 115978.

García-Castillo J, et al. (2025) MicroRNA 196a contributes to the aggressiveness of esophageal adenocarcinoma through the MYC/TERT/NF?B axis. Molecular oncology, 19(11), 3305.

Stamati I, et al. (2025) Anti-HER2, High-DAR Antibody Fragment-Drug Conjugates with a Glucuronide-Based MMAE Linker-Payload Demonstrate Superior Efficacy over IgG-Based ADCs. Molecular cancer therapeutics, 24(9), 1295.

Zenz T, et al. (2025) The Histone Deacetylase Inhibitor Entinostat Mediates HER2 Downregulation in Gastric Cancer, Providing the Basis for Its Particular Efficacy in HER2-Amplified Tumors and in Combination Therapies. *Cancer research and treatment*, 57(3), 781.

Liu D, et al. (2024) Predictive biomarkers for response to TGF- β inhibition in resensitizing chemo(radiated) esophageal adenocarcinoma. *Pharmacological research*, 207, 107315.

Huang YJ, et al. (2024) Targeting c-MET for Endoscopic Detection of Dysplastic Lesions Within Barrett's Esophagus Using EMI-137 Fluorescence Imaging. *Clinical cancer research : an official journal of the American Association for Cancer Research*.

Bozzarelli I, et al. (2024) miRNA-221 and miRNA-483-3p Dysregulation in Esophageal Adenocarcinoma. *Cancers*, 16(3).

Foley K, et al. (2024) SMAD4 and KCNQ3 alterations are associated with lymph node metastases in oesophageal adenocarcinoma. *Biochimica et biophysica acta. Molecular basis of disease*, 1870(1), 166867.

Dings MPG, et al. (2022) Estrogen-related receptor alpha drives mitochondrial biogenesis and resistance to neoadjuvant chemoradiation in esophageal cancer. *Cell reports. Medicine*, 3(11), 100802.

Narusaka T, et al. (2021) Nanog is a promising chemoresistant stemness marker and therapeutic target by iron chelators for esophageal cancer. *International journal of cancer*, 149(2), 347.

Song JH, et al. (2021) Novel Long Noncoding RNA miR205HG Functions as an Esophageal Tumor-Suppressive Hedgehog Inhibitor. *Cancers*, 13(7).

Barber G, et al. (2020) Characterizing caspase-1 involvement during esophageal disease progression. *Cancer immunology, immunotherapy : CII*, 69(12), 2635.

Zhou FY, et al. (2019) Motion sensing superpixels (MOSES) is a systematic computational framework to quantify and discover cellular motion phenotypes. *eLife*, 8.